Cancer treatment and research communications最新文献

{"title":"Implant reconstruction after mastectomy–A review and summary of current literature","authors":"Thomas Kidd,&nbsp;Gerard Mccabe,&nbsp;Joanna Tait,&nbsp;Dhananjay Kulkarni","doi":"10.1016/j.ctarc.2024.100821","DOIUrl":"10.1016/j.ctarc.2024.100821","url":null,"abstract":"<div><h3>Introduction</h3><p>The landscape of breast reconstruction has changed significantly with a shift in focus to include the restoration of a patient's quality of life after cancer. Reconstructive options can be divided into alloplastic (implant based) and autologous (tissue based). This paper aims to provide a current educational summary regarding implant-based reconstruction after breast cancer surgery and review the current literature.</p></div><div><h3>Method</h3><p>A review of the literature was conducted utilising standard PRISMA flowchart. Databases searched included Pubmed, EMBASE, and MEDLINE.</p></div><div><h3>Results</h3><p>Current practice is explored within the text, including types of implants, indications, and surgical approaches. Heterogenous cohorts, surgical technique variation, and selection bias can make comparison of the literature challenging. The major evidence reviews of implant-based reconstruction topics are discussed including, ADM use, radiotherapy, and complications. Despite the benefits of autologous reconstruction, implant-based techniques still represent a significant proportion of reconstructive breast procedures. However, implant-reconstruction is not without its risks and limitations and, with such variety in practice, there remains a lack of high-quality evidence guiding practice. Most importantly, patients need to be counselled about the pros and cons of each choice, particularly with the increasing utilisation of radiotherapy post-reconstruction. Ultimately, the patient and surgeon should reach a decision in full knowledge of the risks and potential outcomes.</p></div><div><h3>Conclusions</h3><p>Further research is required into implant-based reconstructive therapy, which will allow a greater consensus for management and a pathway for both surgeons and patients.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100821"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000339/pdfft?md5=ff6ed00651ee34dc6bcace7f6346b888&pid=1-s2.0-S2468294224000339-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status","authors":"Ivo Abraham ,&nbsp;Jeffrey Crawford ,&nbsp;Lee Schwartzberg","doi":"10.1016/j.ctarc.2024.100824","DOIUrl":"10.1016/j.ctarc.2024.100824","url":null,"abstract":"<div><h3>Introduction</h3><p>Myelosuppression, a challenge in cancer treatment, often results in severe complications. Prophylactic granulocyte colony-stimulating factors, particularly pegfilgrastim, mitigate chemotherapy-induced neutropenia. This narrative review evaluates the role of on-body injector (OBI) devices for pegfilgrastim administration. A comprehensive search strategy of PubMed and AI-powered intuitive search tools, complemented by authors’ contributions, yielded a body of papers presenting evidence on OBI devices, their effectiveness and safety, the benefits and challenges of OBI versus pre-filled syringe administration, patient preferences for pegfilgrastim administration, and economic considerations.</p></div><div><h3>Discussion</h3><p>OBI devices prove effective and safe, with advantages such as reduced clinic visits and enhanced adherence. Studies highlight cost-efficiency and expanded access, emphasizing the socioeconomic context. Patient and provider preferences underscore the potential of OBI devices in cancer care, with implications for healthcare resource utilization and pharmacoeconomics.</p></div><div><h3>Conclusion</h3><p>The value proposition of OBI devices lies in improving patient outcomes, convenience, resource optimization, and enhancing the overall cancer care experience. As biosimilar OBIs enter the market, they may offer cost savings, further influencing their adoption and their positioning as a cost-efficient alternative in cancer care. Ongoing research and technological advancements are expected to contribute to the broader acceptance of OBI devices in cancer care delivery.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100824"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000364/pdfft?md5=d631ce41ffbf10d7eac4dd7d138ac75f&pid=1-s2.0-S2468294224000364-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast conserving therapy: Observational study","authors":"Puttiporn Naowaset","doi":"10.1016/j.ctarc.2025.100885","DOIUrl":"10.1016/j.ctarc.2025.100885","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence of DCIS (DCIS) constitutes 25 % of the newly identified breast cancers. Approximately 35 % of DCIS cases are detected in asymptomatic women during routine mammography screening. The 20-year breast-cancer-specific mortality rate was 3.3 %. Breast-conserving surgery(BCS), followed by radiotherapy, is the treatment of choice. However, an adequate margin for BCS remains unclear. Therefore, we need to investigate the relationship between the margin distance and cancer recurrence.</div></div><div><h3>Methods</h3><div>A total of 4,355 patients with DCIS were assessed between January 1, 2010, and January 31, 2020. Of these, 4,123 patients who had invasive ductal carcinoma co-existing DCIS and who were treated with mastectomy were excluded. Thus, 232 patients with pure DCIS treated with BCS were included. All distant radial margins were measured.</div></div><div><h3>Results</h3><div>A total of 232 patients with DCIS underwent breast-conserving surgery, 169 patients received whole breast radiotherapy, and 63 did not. Most patients received hormone therapy, and as indicated, the median follow-up was 73 months. Recurrence was observed in seven patients. Among them, four had margins &lt;2 mm, while the others had margins &gt; 2 mm. There were no significant differences in disease-free survival (DFS) among the margin statuses.</div></div><div><h3>Conclusion</h3><div>Margins wider than 2 mm did not demonstrate a reduction in local recurrence for women receiving adjuvant whole-breast radiation therapy, supporting the recommendation of a negative margin threshold for surgical management of DCIS.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100885"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification","authors":"Youngkyung Jeon ,&nbsp;Ji-Yeon Kim ,&nbsp;Jin Seok Ahn ,&nbsp;Young-Hyuck Im ,&nbsp;Kyuehee Choi ,&nbsp;Sun Young Jeong ,&nbsp;Yeji Jung ,&nbsp;Jaeyeon Jang ,&nbsp;Dae-Ho Choi ,&nbsp;Joohyun Hong ,&nbsp;Hyo Jung Kim ,&nbsp;Soo Youn Cho ,&nbsp;Yeon Hee Park","doi":"10.1016/j.ctarc.2024.100857","DOIUrl":"10.1016/j.ctarc.2024.100857","url":null,"abstract":"<div><h3>Background</h3><div>The World Health Organization's fifth edition of tumor series classification was published in 2019 and adopted the term ‘Neuroendocrine neoplasm (NEN)’ to encompass all tumor classes with predominant neuroendocrine differentiation (NED). Based on the updated classification of the NEN, we conducted a case series using the Clinical Data Warehouse platform of SMC.</div></div><div><h3>Methods</h3><div>In this retrospective study, breast NENs and invasive breast carcinomas no special type (IBC<img>NST) with NED, were defined as 'NENS’. Based on pathology slide findings, a pathologist reclassified the diagnoses. Clinical presentation, tumor characteristics, and clinical outcomes of breast ‘NENS’ were reviewed retrospectively.</div></div><div><h3>Results</h3><div>A total of 34,370 patients were diagnosed with breast cancer from 1995 to 2022 in SMC, and 14 (0.04 %) patients were diagnosed with breast ‘NENS’: eight NECs, three NETs, and three IBC<img>NST with NED. The patients’ median age was 48.5 years. All patients were treated with curative intent surgery; five patients received neoadjuvant chemotherapy, twelve patients received radiotherapy, six patients received adjuvant chemotherapy, and eight patients received hormone therapy. The median follow-up period for the eight patients with breast NEC was 20.4 months. The median disease-free and overall survival were 14.2 months and 23.6 months, respectively. Patients with NET or IBC<img>NST with NED (<em>n =</em> 6) had an overall favorable outcome, with no deaths, with only one case of disease recurrence.</div></div><div><h3>Conclusion</h3><div>The incidence of primary breast NENS’ was very low (0.04 %) in this single-center study. Among them, primary breast NEC was associated with poor overall survival. Novel treatments are thus required to improve the prognosis of primary breast NEC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100857"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WGCNA and integrative network analysis identify CHRNA5 and CTLA4 as potential therapeutic targets against angiosarcoma","authors":"Trishla Bhatnagar ,&nbsp;Madiha Haider ,&nbsp;Mohd Yasir Khan ,&nbsp;Mohammad Zahid Ashraf","doi":"10.1016/j.ctarc.2024.100862","DOIUrl":"10.1016/j.ctarc.2024.100862","url":null,"abstract":"<div><div>Angiosarcomas are a type of soft-tissue sarcoma characterized by aggressive malignant tumors originating from endothelial cells of blood vessels or lymphatic vessels. Limited studies have been done to explore the molecular pathophysiology of the disease, with rather limited studies involving transcriptomic analyzes. This study was undertaken to identify the shared molecular signatures and gene modules associated with angiosarcomas of various origin. Transcriptomic data analysis of publicly available data was done followed by WGCNA to identify shared signature gene modules. The Maximal Clique Centrality algorithm was applied to gene modules, and unclustered network analysis was conducted on differentially expressed genes to identify true hub genes. The expression of candidate genes in various cancer types was analyzed using GEPIA. WGCNA analysis identified five significant modules, with the most enriched module being associated with angiogenesis and cell junction regulators. The intersection of true hub genes from MCC analysis of WGCNA modules and high-degree nodes from an unclustered network revealed eight consistently overexpressed genes in all angiosarcoma samples.Among the eight enriched genes, CHRNA5 and CTLA4, are exclusively overexpressed in angiosarcoma and not in other cancers of the same tissue origin, with significant drug-protein interactions suggesting their potential as therapeutic targets.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100862"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Evaluating Current Diagnostic and Treatment Challenges in Colorectal Cancer: Strategies for improving care and outcomes in Georgia\"","authors":"Saba Kopadze ,&nbsp;Ivane Kiladze","doi":"10.1016/j.ctarc.2025.100866","DOIUrl":"10.1016/j.ctarc.2025.100866","url":null,"abstract":"<div><h3>Purpose</h3><div>An initial analysis of population-based cancer survival data from Georgia revealed lower CRC survival rates compared to high-income countries. We conducted the study to address this issue and propose strategies for enhancing CRC care.</div></div><div><h3>Patients and Methods</h3><div>We analyzed CRC statistics, reviewed screening programs, and examined published CRC research in Georgia. Finally, we surveyed 16 oncologists from major institutions all over the country to assess molecular testing, treatment standards, and access to modern medications.</div></div><div><h3>Results</h3><div>Despite CRC screening being available in Georgia, late diagnoses persist, with over a 1/3 of cases presenting with acute intestinal obstruction. As a result, 65 % of CRC patients are diagnosed at locally advanced or metastatic stages. All 16 oncologists reported limited molecular testing due to costs, with 13 not routinely performing MSI/MMR and NRAS/KRAS/BRAF testing. Consequently, only 15 % of patients receive anti-EGFR therapy. Oxaliplatin-based therapy is almost universally used for metastatic CRC as the first-line treatment. No CRC clinical trials have been conducted in Georgia over the past three years. Treatment for locally advanced rectalcancer typically includes chemoradiotherapy followed by surgery, with notable variation in multidisciplinary team meeting practices.</div></div><div><h3>Conclusions</h3><div>Study provides several practical recommendations: it is crucial to promote CRC screening programs, enhance access to modern treatment options, and standardize national diagnostic/treatment protocols. There is an urgent need for more clinical trials to increase access to modern therapeutics, as well as to strengthen MDT meetings. These measures are expected to improve CRC care with a further reduction in CRC mortality rates.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100866"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge and practice of health promotive lifestyle toward cervical cancer prevention among women in Africa: A scoping review","authors":"Mary Opeyemi Adigun ,&nbsp;Deborah Tolulope Esan ,&nbsp;Babatunji Emmanuel Oyinloye ,&nbsp;Benedict Tolulope Adeyanju ,&nbsp;Kikelomo Sabainah Olowoyo ,&nbsp;David Bamidele Olawade","doi":"10.1016/j.ctarc.2025.100877","DOIUrl":"10.1016/j.ctarc.2025.100877","url":null,"abstract":"<div><h3>Introduction</h3><div>Cervical cancer remains a significant public health concern among women globally, with a high burden of morbidity and mortality. Despite the existence of empirical evidence about various preventive strategies, the burden of cancer continues to rise, particularly in developing countries like Nigeria. This scoping review aimed to examine the existing literature on the knowledge and practice of health-promotive lifestyle factors for the prevention of cervical cancer among women in Nigeria. This review is driven by the acknowledgment that early detection and prevention are crucial in mitigating the impact of cervical cancer.</div></div><div><h3>Method</h3><div>A systemic search of databases; PubMed, Embase, Google Scholar, Medline, Semantic Scholars was also conducted to identify relevant studies published between 2019 and 2023. Relevant articles were screened for eligibility, and 46 papers were selected. The Joanna Briggs Institute and Preferred Reporting Items for Systematic Review and Meta-analysis Scoping Review Extension (PRISMA-ScR) guidelines were used to analyze the quality of the articles.</div></div><div><h3>Results</h3><div>The study affirmed that various studies have been done concerning knowledge and practice of cervical cancer prevention among women in Africa. The knowledge, attitude and practice of cervical cancer prevention was poor among these women, which has had a direct influence in the poor uptake of cervical cancer screening among Africa women. However, nurse led interventions has been proven to increase knowledge level and screening uptake in experimental groups post intervention.</div></div><div><h3>Conclusions</h3><div>While some women have good knowledge of cervical prevention, the attitude and practice of prevention is poor in many of the studies reviewed. The uptake of screening was low, and some barriers identified encompasses socio-cultural concerns, cost, insufficient health education, limited availability of healthcare services, and consent from partners, while family history of cervical cancer is one of the reasons for uptake of screening in some women.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100877"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer","authors":"Xiao Hu ,&nbsp;Jeffrey H. Lin ,&nbsp;Stacey Pan ,&nbsp;Yana V. Salei ,&nbsp;Susan K. Parsons","doi":"10.1016/j.ctarc.2024.100833","DOIUrl":"10.1016/j.ctarc.2024.100833","url":null,"abstract":"<div><h3>Background</h3><p>The data on immune checkpoint inhibitors (ICI) use in lung cancer individuals generally underrepresented in clinical trials are limited. We aimed to examine the ICI access, safety, and outcome in these populations using real-world data.</p></div><div><h3>Methods</h3><p>Patients with lung cancer newly started on ICIs from 2018 to 2021 were included. Patient factors (age, sex, race, insurance, Charlson comorbidity index (CCI), Eastern Cooperative Oncology Group (ECOG) performance status, histories of autoimmune disease (AD), infection within 3 months before treatment, and brain metastasis) were collected and grouped. Associations of each patient factor with the time-to-treatment initiation (TTI) of ICIs and immune-related adverse events (irAEs) were examined via cumulative incidence analyses and Chi-squared tests, respectively. Log-rank tests and Cox models were used to assess association of patient factors with overall survival (OS).</p></div><div><h3>Results</h3><p>Of 125 patients (median age:70 years (50–88), 68 (54.4 %) males), 9 (7.2 %) had Medicaid/uninsured, 44 (35.2 %) had ECOG ≥ 2, 101 (80.8 %) had CCI ≥ 3, 16 (12.8 %) had ADs, 14 (11.2 %) had infections, and 26 (20.8 %) had brain metastases. In newly diagnosed stage IV patients (<em>N</em> = 62), no difference in TTI was found by patient factors. Fifty irAEs occurred within 12 months and no differences in irAEs occurrence by patient factors. In advanced-stage group (<em>N</em> = 123), OS did not differ by patient factors, except for race (<em>p</em> = 0.045). Whites showed an inferior OS than non-Whites in multivariable regression. (Hazards ratio = 2.82 [1.01–7.87], <em>p</em> = 0.047).</p></div><div><h3>Conclusions</h3><p>Previously poorly represented subgroups were shown to have no significant delays in ICI use, general tolerance, and comparable outcomes. This adds practical evidence to ICI use in clinically and/or socio-demographically marginalized populations.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100833"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000455/pdfft?md5=d6e48f89684fa10847abbc2cc41ad10b&pid=1-s2.0-S2468294224000455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study","authors":"Yuichiro Nishibori ,&nbsp;Hirotsugu Kenmotsu ,&nbsp;Kenju Ando ,&nbsp;Ayumi Tonsho ,&nbsp;Suguru Matsuda ,&nbsp;Meiko Morita ,&nbsp;Motoki Sekikawa ,&nbsp;Kosei Doshita ,&nbsp;Noboru Morikawa ,&nbsp;Keita Miura ,&nbsp;Hiroaki Kodama ,&nbsp;Michitoshi Yabe ,&nbsp;Yuko Iida ,&nbsp;Nobuaki Mamesaya ,&nbsp;Haruki Kobayashi ,&nbsp;Ryo Ko ,&nbsp;Kazushige Wakuda ,&nbsp;Akira Ono ,&nbsp;Tateaki Naito ,&nbsp;Haruyasu Murakami ,&nbsp;Toshiaki Takahashi","doi":"10.1016/j.ctarc.2024.100849","DOIUrl":"10.1016/j.ctarc.2024.100849","url":null,"abstract":"<div><h3>Objectives</h3><div>The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit of adding an immune checkpoint inhibitor (ICI) to the population, the optimal treatment strategy and efficacy of subsequent treatment after relapse remain unclear.</div></div><div><h3>Materials and methods</h3><div>We retrospectively collected data from patients with unresectable LA-NSCLC who completed platinum-based CCRT as first-line treatment. Patients who received molecular-targeted therapy for driver gene alterations or did not receive durvalumab as consolidation therapy following the approval were excluded. We assessed differences in regimen and efficacy of subsequent treatment in patients who underwent durvalumab consolidation therapy (D group) and those who did not (CR group).</div></div><div><h3>Results</h3><div>Among the 62 eligible patients, 32 were assigned to the D group and 30 to the CR group. Patients in the CR group were more frequently treated with an immune checkpoint inhibitor (ICI)-containing regimen than those in the D group (57 % vs. 13 %, <em>p</em> &lt; 0.001). The median overall survival from initiation of subsequent treatment was shorter in the D group than in the CR group (13.0 months vs. 26.7 months, hazard ratio 2.60; 95 % confidence interval: 1.28–2.56, <em>p</em> = 0.008).</div></div><div><h3>Conclusions</h3><div>Patients with unresectable LA-NSCLC who relapsed after durvalumab consolidation therapy received an ICI-containing regimen less frequently, and the efficacy of the subsequent treatment was limited.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100849"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the role of MSH2 and MSH6 gene expression deficiency in prostate cancer progression, a cross-sectional study","authors":"Fatemeh Sharbati,&nbsp;Hedieh Moradi Tabriz,&nbsp;Elham Nazar","doi":"10.1016/j.ctarc.2024.100826","DOIUrl":"10.1016/j.ctarc.2024.100826","url":null,"abstract":"<div><h3>Background</h3><p>Recently, some evidence emphasized the value of MSH2 and MSH6 inactivation and their hypermutation in predicting different cancers. The present consideration is to evaluate the value of MSH2 and MSH6 protein deficient studied by the immunohistochemistry (IHC) method and the tumor behaviors and aggressiveness in prostatic carcinoma.</p></div><div><h3>Methods</h3><p>This cross-sectional study was performed on 80 examples extricated from patients who endured prostate cancer and were planned for radical prostatectomy surgery. The expression levels of the genes were studied by IHC staining.</p></div><div><h3>Results</h3><p>The deficiency in MSH2 and MSH6 expression was revealed in 10.0 % and 11.3 % of patients respectively, while the reduction of simultaneous expression in two genes was found in 6.2 % of patients. In the two subgroups with and without MSH2 and/or MSH6 staining, there was no difference in patients' mean age and history of prostate cancer. There was also no difference in tumor-related behaviors including combined Gleason grade group, tumor stage, vascular invasion, perineural invasion, and prostatic capsular invasion between the groups with and without gene loss.</p></div><div><h3>Conclusion</h3><p>The evaluation of the deficient rate of two genes among patients with prostate cancer to predict the tumor grade and its aggressive behavior needs further study in every population.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100826"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000388/pdfft?md5=fed1219763129e48f95540243616817c&pid=1-s2.0-S2468294224000388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}